Pfizer to settle Celebrex and Bextra suits for $894 million
This article was originally published in Scrip
Executive Summary
Pfizerhas agreed in principle to pay $894 million to resolve most legal claims surrounding its COX-2 inhibitors, Celebrex (celecoxib) and Bextra (valdecoxib).